We are pleased to inform you that SYMATESE has obtained the CE marking for its line of injectable hyaluronic acid-based products, named ESTYME®, based on our exclusive COLD-X TECHNOLOGY1 by SYMATESE™, the fruit of several years of research within SYMATESE which has enabled us to develop an expert range consisting of 5 products.
For Jean-Paul Gérardin, CEO of SYMATESE, “The launch of ESTYME® injectable products in Europe is a key step in an ambitious expansion program, which will also take us into the American, Chinese and Brazilian markets by 2025, enabling us to tackle a market worth 3 billion euros2“.
Dr Benjamin Ascher, MD, Plastic Surgeon and President of IMCAS explains “I had the opportunity to treat the first patients as a clinical investigator with four formulations. From a clinical point of view, I found these injectables easy to use, with great precision, enabling an adapted and personalized correction for each patient”.
We will be rolling out our new range of injectable products on the European and US markets in collaboration with our partner Evolus Inc, who will be enriching its offering with its flagship neurotoxin3, already firmly established on the US market.
You want to know more, read our press release or our announcement video
1 The name of the technology in Europe and the USA is COLD-X TECHNOLOGY by SYMATESE™ and in China, the name is CXLD TECHNOLOGY by SYMATESE™
2 Data IMCAS 2024: global market estimated at 4 billion
3 Respectively named NUCEIVA® and JEUVEAU® in Europe/Australia and the USA
